PHARMACHON 2025 • SATURDAY, JULY 12 • SAN FRANCISCO, CA
SOURCE: BioMarin Pharmaceutical Inc. New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and…
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeSavarirayan, Ravi et al.Genetics in Medicine, Volume 26,…
Boero, Silvio & Vodopiutz, Julia & Maghnie, Mohamad & Bergua, Josep & Ginebreda, Ignacio & Kitoh, Hiroshi & Langendörfer, Micha & Leiva-Gea, Antonio & Malone, Jason & McClure, Philip &…
SOURCE Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight…
This weekend, BioMarin, the Diamond Sponsor for the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, presented new data at the Pediatric Endocrine Society Meeting in Chicago. BioMarin announced positive…
SOURCE: Children’s National Hospital – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of…
